Compare key investment metrics of 신풍제약 and 109820 in real time. Both stocks belong to the 말라리아 관련주 sector. View PER (Price-to-Earnings Ratio), PBR (Price-to-Book Ratio), dividend yield, market capitalization, and 52-week high/low side by side, with automatic highlighting of the leading stock for each metric.
Comparison at a Glance
- By market capitalization, 신풍제약 is larger — ₩428B vs 109820's ₩28B. Larger companies tend to be less volatile, while smaller ones may offer more growth headroom.
- 신풍제약's current price of 8,170원 sits at about 6% of its 52-week range (7,700원–15,990원).
- 109820's current price of 1,392원 sits at about 2% of its 52-week range (1,345원–3,835원).
- This comparison is for reference only, based on publicly available market data, and does not constitute investment advice.
| Metric | 신풍제약 | 109820 |
|---|---|---|
| Price | 8,170원 | 1,392원 |
| PER | 43배 | - |
| PBR | 1.48배 | 1.61배 |
| Market Cap | ₩428B | ₩28B |
| 52-Week High | 15,990원 | 3,835원 |
| 52-Week Low | 7,700원 | 1,345원 |
As of 2026-07-06 · Source: KRX (Naver Finance) public data
Frequently Asked Questions
Which has a lower PER, 신풍제약 or 109820?
PER (Price-to-Earnings Ratio) divides a stock's price by its earnings per share. A lower PER may suggest the stock is undervalued relative to its earnings. Since PER changes with each earnings report, check the real-time comparison table on this page for the latest 신풍제약 and 109820 PER values.
What is the dividend yield difference between 신풍제약 and 109820?
Dividend yield measures annual dividends as a percentage of the stock price. A higher yield means more cash income per dollar invested. The dividend yields of 신풍제약 and 109820 fluctuate with dividend policy changes and stock price movements — check this page's live data for the most current comparison.
How to compare 신풍제약 and 109820?
PFlow's stock comparison page lets you compare key investment metrics side by side — PER, PBR, dividend yield, market cap, and 52-week high/low. Each metric automatically highlights which stock has the advantage. For deeper analysis, visit each stock's dedicated detail page.